Impact of slow-release oral morphine on drug abusing habits in Austria;Der einfluss von retardiertem morphin auf die drogensituation in Österreich

Neuropsychiatrie

Volumn 24, Issue 2, 2010, Pages 108-117

  Beer, Beate ^a   Rabl, Walter ^a   Libiseller, Kathrin ^a   Giacomuzzi, Salvatore ^a   Riemer, Yvonne ^a   Pavlic, Marion ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Drug related deaths; Opiate addiction; Opiate maintenance program; Slow release morphine

Indexed keywords

BUPRENORPHINE; METHADONE; MORPHINE; 6-O-MONOACETYLMORPHINE; MORPHINE 6 ACETATE; MORPHINE DERIVATIVE; NARCOTIC AGENT; TALC;

ARTICLE; AUSTRIA; DRUG ABUSE; HUMAN; MAINTENANCE THERAPY; BRAIN; CAUSE OF DEATH; DELAYED RELEASE FORMULATION; FOREIGN BODY REACTION; HEART MUSCLE; HEROIN DEPENDENCE; INTOXICATION; LUNG; LUNG EMBOLISM; METHODOLOGY; MORPHINE ADDICTION; MORTALITY; ORAL DRUG ADMINISTRATION; PATHOLOGY; POLARIZATION MICROSCOPY; SUBSTANCE ABUSE;

ADMINISTRATION, ORAL; AUSTRIA; BRAIN; CAUSE OF DEATH; DELAYED-ACTION PREPARATIONS; FOREIGN-BODY REACTION; HEROIN DEPENDENCE; HUMANS; LUNG; MICROSCOPY, POLARIZATION; MORPHINE; MORPHINE DEPENDENCE; MORPHINE DERIVATIVES; MYOCARDIUM; NARCOTICS; OVERDOSE; PULMONARY EMBOLISM; SUBSTANCE ABUSE DETECTION; SUBSTANCE ABUSE, INTRAVENOUS; TALC;

EID: 77956988964     PISSN: 09486259     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Kraus L, Augustin R, Frischer M, Kummler P, Uhl A, Wiessing L. Estimating prevalence of problem drug use at national level in countries of the European Union and Norway. Addiction 98, 471-485 (2003).
2. Louria DB. Medical complications of pleasure-giving drugs. Arch Intern Med 123, 82-87 (1969).
3. Mc Lellan AT, Woody GE, O'Brien CP. Development of psychiatric illness in drug abusers. Possible role of drug preference. N Engl J Med 301, 1310-1314 (1979).
4. Rajs J, Falconer B. Cardiac lesions in intravenous drug addicts. Forensic Sci Int 13, 193-209 (1979).
5. Bart G, Piccolo P, Zhang L, Jacobson I, Schaefer RA, Kreek MJ. Markers for hepatitis A, B and C in methadone maintained patients: an unexpectedly high co-infection with silent hepatitis B. Addiction 103, 681-686 (2008).
6. Grebely J, Genoway KA, Raffa JD, Dhadwal G, Rajan T, Showler G, Kalousek K, Duncan F, Tyndall MW, Fraser C, Conway B, Fischer B. Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug Alcohol Depend 93, 141-147 (2008).
7. Cook PA, McVeigh J, Syed Q, Mutton K, Bellis MA. Predictors of hepatitis B and C infection in injecting drug users both in and out of drug treatment. Addiction 96, 1787-1797 (2001).
8. Nordt C, Stohler R. Estimating heroin epidemics with data of patients in methadone maintenance treatment, collected during a single treatment day. Addiction 103, 591-597 (2008).
9. Oldendorf WH, Hyman S, Braun L, Oldendorf SZ. Blood-brain barrier: penetration of morphine, codeine, heroin, and methadone after carotid injection. Science 178, 984-986 (1972).
10. Rook EJ, Huitema AD, van den BW, van Ree JM, Beijnen JH. Pharmacokinetics and pharmacokinetic variability of heroin and its metabolites: review of the literature. Curr Clin Pharmacol 1, 109-118 (2006).
11. Arana GW. The impaired physician: a medical and social dilemma. Gen Hosp Psychiatry 4, 147-154 (1982).
12. Bohigian GM, Croughan JL, Sanders K. Substance abuse and dependence in physicians: an overview of the effects of alcohol and drug abuse. Mo Med 91, 233-239 (1994).
13. Frenois F, Le MC, Cador M. The motivational component of withdrawal in opiate addiction: role of associative learning and aversive memory in opiate addiction from a behavioral, anatomical and functional perspective. Rev Neurosci 16, 255-276 (2005).
14. European Monitoring Centre for Drugs and Drug Addiction. Publications on drug related deaths. http://www.emcdda. europa.eu/stats08/drd/methods (2009).
15. Gesundheit Österreich GmbH, Geschäftsbereich ÖBIG. Suchtgiftbezogene Todesfälle. http://www.bmg.gv.at/cms/site/attachments/3/ 3/5/CH0755/CMS1245848916927/suchtgiftbezogene-todesfaelle-2007korr.pdf (2008).
16. Sergeev B, Karpets A, Sarang A. Prevalence and circumstances of opiate overdose among injection drug users in the Russian Federation. J Urban Health 80, 212-219 (2003).
17. Pfersmann D, Presslich O, Pakesch G, Hollerer E, Pfersmann V. Organization and implementation of the Austrian methadone program and initial results. Nervenarzt 61, 438-443 (1990).
18. Kuntze MF. Der aktuelle Stand opiatgestützter Behandlungen in der Schweiz. Neuropsychiatrie 17, 80-82 (2003).
19. Suchtmittelgesetz. BGBl. I Nr. 112/1997 zuletzt geändert durch BGBl. I Nr. 143/2008. www.ris.bka.gv.at (2009).
20. Weiterbildungsverordnung orale Substitution. BGBl. II Nr. 449/2006 zuletzt geändert durch BGBl. II Nr. 5/2009. www.ris.bka.gv.at (2009).
21. Suchtgiftverordnung. BGBl. II Nr. 374/1997 zuletzt geändert durch BGBl. II Nr. 173/2009. www.ris.bka.gv.at (2009).
22. McCarthy J. Quantitative urine drug monitoring in methadone programs: potential clinical uses. J Psychoactive Drugs 26, 199-206 (1994).
23. Pavlic M, Libiseller K, Grubwieser P, Rabl W. Cross-reactivity of the CEDIA buprenorphine assay with opiates: an Austrian phenomenon? Int J Legal Med 119, 378-381 (2005).
24. Kresina TF, Bruce RD, Lubran R, Clark HW. Integration of viral hepatitis services into opioid treatment programs. J Opioid Manag 4, 369-381 (2008).
25. Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Taylor RJ, Fry-Smith A, Day E, Lintzeris N, Roberts T, Burls A, Taylor RS. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess 11, 1-171 (2007).
26. Backmund M, Meyer K, Eichenlaub D, Schutz CG. Predictors for completing an inpatient detoxification program among intravenous heroin users, methadone substituted and codeine substituted patients. Drug Alcohol Depend 64, 173-180 (2001).
27. Gruber VA, Delucchi KL, Kielstein A, Batki SL. A randomized trial of 6-month methadone maintenance with standard or minimal counseling versus 21-day methadone detoxification. Drug Alcohol Depend 94, 199-206 (2008).
28. Giacomuzzi SM, Riemer Y, Kemmler G, Ertl M, Richter R, Rossler H, Hinterhuber H. Subjective wellbeing and somatic markers in methadone substitution. Evaluation of 61 heroin addicts. Fortschr Med Orig 119, 103-108 (2001).
29. Davoli M, Bargagli AM, Perucci CA, Schifano P, Belleudi V, Hickman M, Salamina G, Diecidue R, Vigna-Taglianti F, Faggiano F. Risk of fatal overdose during and after specialist drug treatment: the VEdeTTE study, a national multi-site prospective cohort study. Addiction 102, 1954-1959 (2007).
30. Dole VP, Nyswander M. A Medical Treatment for Diacetylmorphine (Heroin) Addiction. A Clinical Trial with Methadone Hydrochloride. JAMA 193, 646-650 (1965).
31. Wolff K, Rostami-Hodjegan A, Shires S, Hay AW, Feely M, Calvert R, Raistrick D, Tucker GT. The pharmacokinetics of methadone in healthy subjects and opiate users. Br J Clin Pharmacol 44, 325-334 (1997).
32. Fugelstad A, Stenbacka M, Leifman A, Nylander M, Thiblin I. Methadone maintenance treatment: the balance between life-saving treatment and fatal poisonings. Addiction 102, 406-412 (2007).
33. Jasinski DR, Pevnick JS, Griffith JD. Human pharmacology and abuse po tential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry 35, 501-516 (1978).
34. Walsh SL, Preston KL, Bigelow GE, Stitzer ML. Acute administration of buprenorphine in humans: partial agonist and blockade effects. J Pharmacol Exp Ther 274, 361-372 (1995).
35. Kraigher D, Jagsch R, Gombas W, Ortner R, Eder H, Primorac A, Fischer G. Use of slow-release oral morphine for the treatment of opioid dependence. Eur Addict Res 11, 145-151 (2005).
36. Bochner F, Somogyi AA, Christrup LL, Larsen U, Danz C, Elbaek K. Comparative Pharmacokinetics of Two Modified-Release Oral Morphine Formulations (Reliadol and Kapanol) and an Immediate-Release Morphine Tablet (Morfin 'DAK') in Healthy Volunteers. Clin Drug Invest 17, 59-66 (1999).
37. VIDAL. Österreichische Arzneimittel-Fachinformation (2009).
38. Fischer G, Jagsch R, Eder H, Gombas W, Etzersdorfer P, Schmidl-Mohl K, Schatten C, Weninger M, Aschauer HN. Comparison of methadone and slow-release morphine maintenance in pregnant addicts. Addiction 94, 231-239 (1999).
39. Kraigher D, Ortner R, Eder H, Schindler S, Fischer G. Slow-release morphine hydrochloride for maintenance therapy of opioid dependence. Wien Klin Wochenschr 114, 904-910 (2002).
40. Mitchell TB, White JM, Somogyi AA, Bochner F. Slow-release oral morphine versus methadone: a crossover comparison of patient outcomes and acceptability as maintenance pharmacotherapies for opioid dependence. Addiction 99, 940-945 (2004).
41. Vasilev GN, Alexieva DZ, Pavlova RZ. Safety and efficacy of oral slow release morphine for maintenance treatment in heroin addicts: a 6-month open noncomparative study. Eur Addict Res 12, 53-60 (2006).
42. Kastelic A, Dubajic G, Strbad E. Slowrelease oral morphine for maintenance treatment of opioid addicts intolerant to methadone or with inadequate withdrawal suppression. Addiction 103, 1837-1846 (2008).
43. Österreichische Gesellschaft für Gerichtliche Medizin (ÖGGM). Richtlinien. www.oeggm.com (2009).
44. Cone EJ, Welch P, Mitchell JM, Paul BD. Forensic drug testing for opiates: I. Detection of 6-acetylmorphine in urine as an indicator of recent heroin exposure; drug and assay considerations and detection times. J Anal Toxicol 15, 1-7 (1991).
45. Haller R, Hinterhuber H, Mann K. Empfehlung zur Substitutionstherapie. Neuropsychiatrie 20, 140-150 (2006).
46. Giacomuzzi SM, Ertl M, Pavlic M, Libiseller K, Riemer Y, Kemmler G, Rössler H, Grubwieser P, Rabl W, Hinterhuber H. Maintenance Treatment of Opioid Dependence and Patterns of Drug Use - Results of a 4-Year Trial. Letters in Drug Design & Discovery 3, 731-740 (2006).
47. Roadside Testing Assessment (ROSITA). www.rosita.org (2009).